Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, ICIs have been used clinically since 2015 for patients with advanced/metastatic NSCLC without epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Andrea, Stratmann, Jan A., Shaid, Shabnam, Niklas, Nicolas, Calleja, Alan, Ubhi, Harveen, Munro, Robin, Waldenberger, Daniela, Carroll, Robert, Daumont, Melinda J., Penrod, John R., Lacoin, Laure, Rohde, Gernot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838033/
https://www.ncbi.nlm.nih.gov/pubmed/36639770
http://dx.doi.org/10.1186/s12890-022-02288-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838033/
https://www.ncbi.nlm.nih.gov/pubmed/36639770
http://dx.doi.org/10.1186/s12890-022-02288-1

Ejemplares similares